摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(tert-butoxycarbonylisopropylamino)propyl tosylate | 905449-67-4

中文名称
——
中文别名
——
英文名称
3-(tert-butoxycarbonylisopropylamino)propyl tosylate
英文别名
3-[(2-Methylpropan-2-yl)oxycarbonyl-propan-2-ylamino]propyl 4-methylbenzenesulfonate
3-(tert-butoxycarbonylisopropylamino)propyl tosylate化学式
CAS
905449-67-4
化学式
C18H29NO5S
mdl
——
分子量
371.498
InChiKey
UERPNTPXQFJOAS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    25
  • 可旋转键数:
    9
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    81.3
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90
    摘要:
    Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways. Its inactivation may result in targeting multiple molecular alterations and, thus, in reverting the transformed phenotype. The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone. The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented. The study identifies water soluble derivatives (> 5 mM in PBS pH 7.4) of nanomolar potency (IC50 similar to 50 nM) in cellular and animal models of cancer. Binding affinities of these compounds for Hsp90 correlate well with their biological activities. When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenocyrafted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors.
    DOI:
    10.1021/jm0508078
  • 作为产物:
    参考文献:
    名称:
    Identification of Potent Water Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90
    摘要:
    Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways. Its inactivation may result in targeting multiple molecular alterations and, thus, in reverting the transformed phenotype. The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone. The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented. The study identifies water soluble derivatives (> 5 mM in PBS pH 7.4) of nanomolar potency (IC50 similar to 50 nM) in cellular and animal models of cancer. Binding affinities of these compounds for Hsp90 correlate well with their biological activities. When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenocyrafted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors.
    DOI:
    10.1021/jm0508078
  • 作为试剂:
    参考文献:
    名称:
    J. Med. Chem. 2006, 49, 381-390
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] NEW COMPOUNDS AS HSP90 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE LA HSP90
    申请人:CRYSTAX PHARMACEUTICALS S L
    公开号:WO2009007399A1
    公开(公告)日:2009-01-15
    The invention provides novel compounds of formula (I) wherein: one of the a, b, c or d members is a nitrogen atom and the remaining members are carbon atoms; and R3 is a radical selected from the group consisting of: -S-R14 and -CH2-R15.The compounds of formula (I) are useful for treating diseases mediated by a heat shock protein 90 (Hsp 90).
    该发明提供了式(I)的新化合物,其中:a、b、c或d成员中的一个是氮原子,其余成员是碳原子;R3是从以下组成的基团中选择的:-S-R14和-CH2-R15。式(I)的化合物对于治疗由热休克蛋白90(Hsp 90)介导的疾病是有用的。
  • 一组具有结合gp96蛋白的能力的化合物及其在 抗乳腺癌中的应用
    申请人:北京中科永邦生物科技有限公司
    公开号:CN103570717B
    公开(公告)日:2016-05-11
    本发明公开了一组具有结合gp96蛋白的能力的化合物及其在抗乳腺癌中的应用。本发明提供了一组化合物,为如下(a)或(b):(a)式(Ⅲ)所示的化合物A3、式(Ⅱ)所示的化合物A2、式(Ⅳ)所示的化合物A4、式(Ⅵ)所示的化合物A6、式(Ⅴ)所示的化合物A5或式(Ⅰ)所示的化合物A1;(b)将(a)所述的化合物进行官能团替换且具有相同功能的腺嘌呤类衍生物。本发明提供的腺嘌呤生物抑制gp96后能明显下调HER2,抑制乳腺癌细胞增殖、促进乳腺癌细胞凋亡,降低乳腺癌细胞的侵袭性,对体内乳腺癌肿瘤具有明显的抑制作用。本发明对于癌症的治疗,特别是乳腺癌的治疗具有重大价值。
  • Small-Molecule Hsp90 Inhibitors
    申请人:Chiosis Gabriela
    公开号:US20080253965A1
    公开(公告)日:2008-10-16
    Hsp90 inhibitors are provided having the formula: with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO 2 . alkyl, COO-alkyl, KH 2 , OH, CN, SO 2 X 5 , NO 2 , NO, C═SR 2 NSO 2 X 5 , C═OR 2 , where X 5 is F, NH2, alkyl or H, and R 2 is alkyl, NH 2 , NH-alkyl or O-alkyl, C 1 to C 6 alkyl or alkoxy; or wherein X 1 has the formula -0-(CH 2 ) n -0-, wherein n is an integer from O to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5′-position and the other at the 4′-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.
    提供具有以下公式的Hsp90抑制剂:右侧芳基基团上具有2'、4'、5'取代模式。X1代表位于芳基团的4'和5'位置的两个取代基,可以相同或不同,其中X1选自卤素、烷基、烷氧基、卤代烷氧基、羟基烷基、吡咯基、可选取代的芳氧基、烷基基、二烷基基、基甲酰、酰胺、烷基酰胺、二烷基酰胺、酰胺基、烷基磺酰胺基、三卤甲氧基、三卤代碳基、代烷基、SO2.烷基、COO-烷基、KH2、OH、CN、SO2X5、NO2、NO、C═SR2NSO2X5、C═OR2,其中X5为F、NH2、烷基或H,R2为烷基、NH2、NH-烷基或O-烷基,C1到C6烷基或烷氧基;或X1具有公式-0-(CH2)n-0-,其中n是0到2的整数,优选为1或2,其中一个氧原子与芳环的5'位置键合,另一个氧原子键合于4'位置。这些化合物在癌症治疗和放射性成像配体方面有用。
  • Small-Molecule HSP90 Inhibitors
    申请人:Chiosis Gabriela
    公开号:US20110104054A1
    公开(公告)日:2011-05-05
    Hsp90 inhibitors having are provided having the formula: with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO 2- alkyl, COO-alkyl, KH 2 , OH, CN, SO 2 X 5 , NO 2 , NO, C═SR 2 NSO 2 X 5 , C═OR 2 , where X 5 is F, NH2, alkyl or H, and R 2 is alkyl, NH 2 , NH-alkyl or O-alkyl, C 1 to C 6 alkyl or alkoxy; or wherein X 1 has the formula -0-(CH 2 ) n -0-, wherein n is an integer from O to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5′-position and the other at the 4′-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.
    提供具有以下公式的Hsp90抑制剂:右侧芳基基团上具有2′,4′,5′-取代模式。X1代表在芳基团上的4′和5′位置上排列的两个取代基,其中X1从卤素,烷基,烷氧基,卤代烷氧基,羟基烷基,吡咯基,可选择取代的芳氧基,烷基基,二烷基基,基甲酰,酰胺,烷基酰胺,二烷基酰胺,酰胺基,烷基磺酰胺基,三卤甲氧基,三卤代碳基,代烷基,SO2-烷基,COO-烷基,KH2,OH,CN,SO2X5,NO2,NO,C═SR2NSO2X5,C═OR2,其中X5为F,NH2,烷基或H,而R2为烷基,NH2,NH-烷基或O-烷基,C1到C6烷基或烷氧基;或其中X1具有公式-0-(CH2)n-0-,其中n是从O到2的整数,优选为1或2,其中一个氧原子与芳环的5′位置连接,另一个氧原子与芳环的4′位置连接。这些化合物在癌症治疗和放射成像配体中有用。
  • Small-molecule Hsp90 Inhibitors
    申请人:Chiosis Gabriela
    公开号:US20110312980A1
    公开(公告)日:2011-12-22
    Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    嘌呤支架Hsp90抑制剂在治疗应用和放射性成像配体中很有用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫